INSM - NASDAQ

Insmed Incorporated

INSM·NASDAQ

$103.86

+0.13%

HealthcareBiotechnology

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$22.51B

EPS-6.4100

P/E Ratio-16.20

Earnings Date08/06/2026

2.26B

Assets

12%

3Y+37.0%

5Y+184.0%

10Y+852.0%

1.53B

Total Liabilities

-12%

3Y-3.0%

5Y+193.0%

10Y+1728.0%

738.98M

Total Equity

159%

3Y+740.0%

5Y+168.0%

10Y+378.0%

Insmed Incorporated Funding & Solvency Profile

INSM · NASDAQ

Current Assets

Cash & Cash Equivalents510.44M

Net Receivables140.86M

Inventory132.07M

Other Current Assets91.24M

Total Current Assets2 B

Non-Current Assets

Property, Plant & Equipment139.21M

Goodwill & Intangible Assets233.76M

Long-Term Investments0.00

Other Non-Current Assets97.38M

Total Non-Current Assets237 M

Total Assets

2.26B

Financial Health Analysis

Current Ratio

3.83x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

2.06x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

1 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

79% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Insmed Incorporated Balance Sheet

INSM • NASDAQ

Insmed Incorporated Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	510.4M	555M	482.4M	1.1B	716.8M	532.8M	487.4M	495.1M	381.2M	162.6M	282.9M	159.2M	113.9M	90.8M	14.8M	10.7M	12.7M	2.1M	16.5M	24.1M
Short-Term Investments	919.6M	878.8M	298.1M	74.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2M	61.4M	97.3M	109.4M	252K	0.0	0.0
Cash & Short-Term Investments	1.4B	1.4B	780.4M	1.1B	716.8M	532.8M	487.4M	495.1M	381.2M	162.6M	282.9M	159.2M	113.9M	92.9M	76.3M	108M	122.2M	2.4M	16.5M	24.1M
Net Receivables	140.9M	52M	41.2M	29.7M	24.4M	16.6M	19.2M	5.5M	0.0	0.0	0.0	0.0	0.0	0.0	757K	471K	2.3M	122K	250K	241K
Accounts Receivables	140.9M	52M	41.2M	29.7M	24.4M	16.6M	19.2M	5.5M	0.0	0.0	0.0	0.0	0.0	0.0	757K	471K	245K	122K	250K	241K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2M	0.0	0.0	0.0
Inventory	132.1M	98.6M	83.2M	69.9M	67M	49.6M	28.3M	7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	576K
Prepaids	0.0	0.0	0.0	0.0	28.9M	24M	20.2M	11.3M	8.3M	5.8M	5.2M	5.5M	2.3M	643K	370K	277K	159K	74K	244K	0.0
Other Current Assets	91.2M	37.2M	24.2M	25.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	494K
Total Current Assets	1.8B	1.6B	929.1M	1.3B	837M	622.9M	555.2M	518.9M	389.4M	168.4M	288.1M	164.7M	116.2M	93.6M	77.4M	108.8M	124.6M	2.6M	17M	25.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	139.2M	115.6M	104.4M	102.1M	95.5M	97.2M	113.1M	22.6M	12.4M	10M	8.1M	7.5M	1.8M	1.7M	1.9M	1.1M	0.0	0.0	4K	8K
Goodwill	136.1M	136.1M	136.1M	136.1M	136.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3M	0.0	0.0	0.0	0.0
Intangible Assets	97.7M	58.7M	63.7M	68.8M	73.8M	49.3M	53.7M	58.7M	58.2M	58.2M	58.2M	58.2M	58.2M	58.2M	58.2M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	233.8M	194.8M	199.8M	204.9M	209.9M	49.3M	53.7M	58.7M	58.2M	58.2M	58.2M	58.2M	58.2M	58.2M	58.2M	6.3M	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	50M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1M	2.2M	2.1M	0.0	0.0	0.0
Other Non-Current Assets	97.4M	93.2M	96.6M	76.1M	51M	26.8M	20.3M	4.3M	2M	1.3M	2.1M	416K	323K	117K	212K	77.9M	2K	2.2M	2.5M	2.9M
Total Non-Current Assets	470.4M	403.6M	400.8M	383.1M	406.5M	173.3M	187.1M	85.6M	72.6M	69.5M	68.4M	66.2M	60.3M	60M	62.4M	87.5M	2.1M	2.2M	2.5M	2.9M
Total Assets	2.3B	2B	1.3B	1.7B	1.2B	796.2M	742.3M	604.6M	462M	238M	356.6M	230.9M	176.5M	153.6M	139.8M	196.3M	126.7M	4.8M	19.5M	28.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	79.9M	73M	74.4M	57.3M	42.4M	46.3M	16.3M	18.2M	14.7M	10.4M	7.5M	9.2M	5.9M	7.1M	2.3M	1.5M	312K	1.3M	904K	7.2M
Accounts Payable	79.9M	73M	65.4M	50.5M	35.8M	42.9M	13.2M	17.7M	14.7M	10.4M	7.5M	9.2M	5.9M	7.1M	2.3M	1.5M	312K	1.3M	904K	7.2M
Other Payables	0.0	0.0	9M	6.9M	6.7M	3.4M	3.1M	409K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	111.5M	80.3M	84.9M	82.1M	49.1M	34.4M	37.3M	37.8M	17.1M	9.9M	6.7M	5.3M	4.2M	3.2M	1.1M	1.3M	1.7M	1.4M	503K	1.1M
Short Term Debt	19.3M	16.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	0.0	3.3M	3M	0.0	0.0	208K	1.6M	1.3M	0.0
Capital Lease Obligations (Current)	0.0	0.0	10.6M	8.1M	10.1M	12.6M	12.3M	0.0	0.0	0.0	0.0	0.0	64K	96K	114K	81K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	552K	530K	470K	0.0	0.0
Other Current Liabilities	258.2M	127.7M	55.6M	42.7M	33.5M	25.6M	19.4M	23.7M	12.8M	7.7M	5M	5.1M	3M	2.4M	951K	0.0	0.0	113K	1M	1.4M
Total Current Liabilities	468.9M	297.5M	225.6M	190.2M	135.2M	118.8M	85.2M	79.7M	44.7M	28M	22.3M	19.6M	16.5M	15.7M	4.5M	3.3M	2.8M	4.9M	3.7M	9.7M
NON-CURRENT LIABILITIES
Long Term Debt	716M	1.3B	1.2B	1.1B	566.6M	356.3M	335.9M	316.6M	55.6M	54.8M	22M	24.9M	16.3M	16.2M	0.0	0.0	0.0	487K	2.1M	3.2M
Other Non-Current Liabilities	307.8M	144.7M	242.8M	208.5M	95.7M	9.2M	10.6M	0.0	765K	693K	572K	141K	380K	647K	923K	0.0	0.0	2.2M	2.2M	1.6M
Total Non-Current Liabilities	1.1B	1.4B	1.4B	1.4B	697.9M	401.5M	395.4M	316.6M	56.3M	55.5M	22.6M	25M	16.7M	16.9M	1.1M	83K	0.0	2.7M	4.3M	4.8M
Capital Lease Obligations	32.9M	33.2M	48.7M	52.6M	45.7M	48.5M	61.1M	0.0	0.0	0.0	0.0	0.0	64K	160K	1.2M	164K	0.0	0.0	0.0	0.0
Total Liabilities	1.5B	1.7B	1.7B	1.6B	833M	520.3M	480.6M	396.3M	101M	83.5M	44.9M	44.6M	33.2M	32.7M	5.6M	3.4M	2.8M	7.6M	8M	14.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	918K	0.0	0.0	0.0	0.0
Common Stock	2.1M	1.8M	1.5M	1.4M	1.2M	1M	897K	773K	766K	620K	618K	498K	391K	315K	248K	1.6M	1.3M	1.2M	1.2M	1M
Additional Paid-In Capital	6.4B	4.6B	3.1B	2.8B	2.7B	2.1B	1.8B	1.5B	1.3B	919.2M	900M	656.5M	534.6M	455.3M	427.7M	423.9M	350.2M	342.4M	341.3M	323.7M
Retained Earnings	-5.6B	-4.4B	-3.4B	-2.7B	-2.3B	-1.8B	-1.5B	-1.3B	-957.9M	-765.2M	-589M	-470.8M	-391.6M	-335.5M	-294.2M	-234.5M	-228.1M	-346.4M	-330.8M	-310.8M
Accumulated Other Comprehensive Income/Loss	1.5M	-2.3M	-745K	756K	968K	193K	-10K	-9K	-3K	-65K	-5.3M	-3.3M	-3.6M	0.0	450K	993K	445K	0.0	-242K	-503K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	790K	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	739M	285.4M	-331.9M	88M	410.5M	275.9M	261.7M	208.3M	361.1M	154.5M	311.7M	186.2M	143.3M	120.9M	134.3M	192.8M	123.9M	-2.8M	11.5M	13.9M
Total Equity	739M	285.4M	-331.9M	88M	410.5M	275.9M	261.7M	208.3M	361.1M	154.5M	311.7M	186.2M	143.3M	120.9M	134.3M	192.8M	123.9M	-2.8M	11.5M	13.9M
SUMMARY
Total Liabilities & Equity	2.3B	2B	1.3B	1.7B	1.2B	796.2M	742.3M	604.6M	462M	238M	356.6M	230.9M	176.5M	153.6M	139.8M	196.3M	126.7M	4.8M	19.5M	28.3M
Total Investments	919.6M	878.8M	298.1M	74.2M	50M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2M	63.5M	99.5M	111.5M	252K	0.0	0.0
Total Debt	768.2M	1.3B	1.2B	1.2B	612.3M	404.8M	397M	316.6M	55.6M	54.8M	25.1M	24.9M	19.7M	19.4M	280K	164K	208K	2.1M	3.4M	3.2M
Net Debt	257.7M	759.1M	721.6M	103.8M	-104.5M	-127.9M	-90.4M	-178.5M	-325.6M	-107.8M	-257.7M	-134.4M	-94.2M	-71.4M	-14.6M	-10.6M	-12.5M	-43K	-13.1M	-21M
Shares Outstanding	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469	213,273,469

SEC Filings

INSM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 15, 2026	May 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 01, 2026	May 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 19, 2026	February 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 17, 2025	December 17, 2025	2025	View Filing

Showing 1 to 10 of 524 filings

Related Guides

Blog Categories

Continue your INSM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.